Drawing for BIOSHIN

USPTO serial 87817056

BIOSHIN

Reviewed by CopyMark Law Group

Reg. 6679806Status 700Registered
Filing date
Status date
Registration date
Mar 22, 2022
Examiner
KAJUBI, ELIZABETH N
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BIOSHIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monica Riva Talley

Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.1100 New York Avenue, N.W.Washington, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive useACTIVEJun 19, 2021

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 17, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 17, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 17, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 17, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 17, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 11, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 22, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 12, 2022SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Feb 11, 2022CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Feb 3, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 3, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 3, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 4, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 4, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 4, 2021CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 27, 2021SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jun 24, 2021IUAFUSE AMENDMENT FILED—
Jun 24, 2021EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Dec 24, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 23, 2020EX5GSOU EXTENSION 5 GRANTED—
Dec 21, 2020EXT5SOU EXTENSION 5 FILED—
Dec 21, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 1, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 30, 2020EX4GSOU EXTENSION 4 GRANTED—
Jun 30, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 17, 2020EXT4SOU EXTENSION 4 FILED—
Jun 17, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 21, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 19, 2019EX3GSOU EXTENSION 3 GRANTED—
Dec 19, 2019EXT3SOU EXTENSION 3 FILED—
Dec 19, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 23, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 23, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 25, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 21, 2019EX2GSOU EXTENSION 2 GRANTED—
Jun 21, 2019EXT2SOU EXTENSION 2 FILED—
Jun 21, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 12, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 10, 2018EX1GSOU EXTENSION 1 GRANTED—
Sep 10, 2018EXT1SOU EXTENSION 1 FILED—
Sep 10, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 26, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 1, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 1, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 11, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 27, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 27, 2018DOCKASSIGNED TO EXAMINER—
Mar 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 5, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance